6CM
AMLX icon

683 Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

683 Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Hold
96,600
– – 0.09% 110
2026
Q1 		$1.34M Buy
+96,600
New +$1.36M 0.07% 128

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

683 Capital Management's AMLX Position: Q2 2026 in Review

683 Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 16% in Q2 2026, selling an estimated $3.87M and leaving 1,279,512 shares worth $23M. The position accounts for 1.13% of the portfolio, ranked #23.

683 Capital Management first reported a position in AMLX in Q1 2022 and has held it in 11 quarters since. The position peaked at $23.9M in Q3 2025. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • 683 Capital Management held 1,279,512 shares of Amylyx Pharmaceuticals worth $23M as of Q2 2026.
  • 683 Capital Management sold 250,488 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $3.87M.
  • Amylyx Pharmaceuticals made up 1.13% of 683 Capital Management's portfolio in Q2 2026, its #23 holding.
  • 683 Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
  • 683 Capital Management's Amylyx Pharmaceuticals position peaked at $23.9M in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.